Trastuzumab (Herceptin)

Herceptin (Trastuzumab) – 600 mg/5 ml
Herceptin is a monoclonal antibody specifically designed to target and block the HER2 receptor, a protein overexpressed in some cancers, such as breast and gastric cancers. By inhibiting the HER2 protein, Herceptin helps in slowing down or halting the growth of cancer cells.

This therapy is commonly used in combination with other chemotherapy agents and is administered as a subcutaneous injection, offering ease of use and reduced infusion time. Herceptin is recognized for its efficacy in improving survival rates and enhancing the quality of life for patients with HER2-positive cancers.

Indications:

• HER2-positive breast cancer (early and metastatic stages).
• HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Benefits:

• Targets HER2 protein with precision, minimizing damage to normal cells.
• Enhances the effects of chemotherapy.
• Improves patient outcomes in HER2-positive cancer cases.

Usage and Dosage:
Administered as a 600 mg/5 ml subcutaneous injection under the guidance of a healthcare professional. Dosage and treatment duration depend on the patient’s condition and medical history.

Precautions:

• Not recommended for patients with known hypersensitivity to trastuzumab or any of its components.
• Should be used with caution in patients with pre-existing cardiac conditions.

Storage Instructions:
Store in a refrigerator at 2°C to 8°C. Protect from light and do not freeze.

Note:
This product requires a prescription and should be used under the supervision of a qualified healthcare professional.

Disclaimer: The information provided here is for educational purposes only and should not replace professional medical advice. Always consult with a healthcare provider for medical guidance.